Stock Research: Aquestive Therapeutics

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Aquestive Therapeutics

NMQ:AQST US03843E1047
60
  • Value
    72
  • Growth
    32
  • Safety
    Safety
    40
  • Combined
    47
  • Sentiment
    79
  • 360° View
    360° View
    60
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Aquestive Therapeutics, Inc. is a pharmaceutical company developing orally administered and topical gel products. It operates in the pharmaceutical industry with products like Anaphylm, AQST-108, Libervant, Suboxone, and Emylif, and commercializes its products in the United States and globally through licensees. In the last fiscal year, the company had a market cap of $403 million, profits of $40 million, revenue of $58 million, and 142 employees.

more
Index
NASDAQ
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 27-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
72 49 51 73
Growth
32 31 99 13
Safety
Safety
40 69 40 29
Sentiment
79 50 73 70
360° View
360° View
60 44 93 40
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
67 85 88 61
Opinions Change
87 50 50 94
Pro Holdings
n/a 49 83 55
Market Pulse
26 21 11 8
Sentiment
79 50 73 70
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
72 49 51 73
Growth
32 31 99 13
Safety Safety
40 69 40 29
Combined
47 51 83 11
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
34 15 33 62
Price vs. Earnings (P/E)
64 42 42 42
Price vs. Book (P/B)
84 93 89 92
Dividend Yield
1 1 1 1
Value
72 49 51 73
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
21 1 55 49
Profit Growth
11 4 91 33
Capital Growth
84 91 81 13
Stock Returns
52 75 95 41
Growth
32 31 99 13
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
5 74 46 38
Refinancing
84 65 49 43
Liquidity
53 29 31 34
Safety Safety
40 69 40 29

Similar Stocks

Discover high‑ranked alternatives to Aquestive Therapeutics and broaden your portfolio horizons.

Global Payments

NYQ:GPN
Country: USA
Industry: Other Financial Services
Size: X-Large
Full Stock Analysis

Omnicom

NYQ:OMC
Country: USA
Industry: Advertising
Size: X-Large
Full Stock Analysis

Mosaic

NYQ:MOS
Country: USA
Industry: Fertilizers & Agricultural Chemicals
Size: X-Large
Full Stock Analysis

Labcorp

NYQ:LH
Country: USA
Industry: Health Care Services
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This is a highly risky stock investment proposition as all consolidated ranks are below-average. There are no compelling arguments to support this stock based on current information. It is not recommended for any investor profile. However, performance does change, so it could we worth keepin on a watchlist.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: